Vanguard Capital Management
XERS icon

Vanguard Capital Management’s Xeris Biopharma Holdings XERS Stock Holding History

Vanguard Capital Management’s Portfolio XERS Stock Details XERS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$58.1M Buy
7,340,229
+359,347
+5% +$2.29M ﹤0.01% 1856
2026
Q1 		$40.5M Buy
+6,980,882
New +$46.3M ﹤0.01% 1971

Other funds holding XERS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
RA
Rosalind Advisors Toronto, Ontario, Canada $269M AUM 103.38% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Vanguard Capital Management's XERS Position: Q2 2026 in Review

Vanguard Capital Management increased its Xeris Biopharma Holdings (XERS) stake by 5.1% in Q2 2026, buying an estimated $2.29M and bringing the position to 7,340,229 shares worth $58.1M. The position accounts for ﹤0.01% of the portfolio, ranked #1856.

Vanguard Capital Management first reported a position in XERS in Q1 2026 and has held it in 2 quarters since. 236 funds tracked by Wall St. Rank hold XERS as of Q2 2026.

  • Vanguard Capital Management held 7,340,229 shares of Xeris Biopharma Holdings worth $58.1M as of Q2 2026.
  • Vanguard Capital Management bought 359,347 Xeris Biopharma Holdings shares in Q2 2026, an estimated $2.29M.
  • Xeris Biopharma Holdings made up ﹤0.01% of Vanguard Capital Management's portfolio in Q2 2026, its #1856 holding.
  • Vanguard Capital Management first reported a position in Xeris Biopharma Holdings in Q1 2026 and has held it in 2 quarters since.
  • 236 funds tracked by Wall St. Rank held Xeris Biopharma Holdings as of Q2 2026.

Based on Vanguard Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.